(GPAT) GP-Act III Acquisition - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
GPAT: No specific products, Merger, Acquisition, Business Combination
GP-Act III Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as GP Investments Acquisition Corp. II and changed its name to GP-Act III Acquisition Corp. in November 2020. GP-Act III Acquisition Corp. was incorporated in 2020 and is based in New York, New York. Web URL: https://www.gp-act3.com
Additional Sources for GPAT Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GPAT Stock Overview
| Market Cap in USD | 365m |
| Sector | Financial Services |
| Industry | Shell Companies |
| GiC Sub-Industry | Diversified Financial Services |
| IPO / Inception | 2024-07-01 |
GPAT Stock Ratings
| Growth 5y | 45.4% |
| Fundamental | -19.9% |
| Dividend | - |
| Rel. Strength Industry | -92 |
| Analysts | - |
| Fair Price Momentum | 9.46 USD |
| Fair Price DCF | - |
GPAT Dividends
No Dividends PaidGPAT Growth Ratios
| Growth Correlation 3m | 94.4% |
| Growth Correlation 12m | 94.7% |
| Growth Correlation 5y | 94.7% |
| CAGR 5y | 1.80% |
| CAGR/Mean DD 5y | 14.15 |
| Sharpe Ratio 12m | -1.80 |
| Alpha | -3.03 |
| Beta | 0.02 |
| Volatility | 3.11% |
| Current Volume | 6k |
| Average Volume 20d | 19.7k |
What is the price of GPAT stocks?
As of January 22, 2025, the stock is trading at USD 10.17 with a total of 5,986 shares traded.
Over the past week, the price has changed by +0.10%, over one month by +0.10%, over three months by +0.89% and over the past year by +1.80%.
As of January 22, 2025, the stock is trading at USD 10.17 with a total of 5,986 shares traded.
Over the past week, the price has changed by +0.10%, over one month by +0.10%, over three months by +0.89% and over the past year by +1.80%.
Is GP-Act III Acquisition a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, GP-Act III Acquisition is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -19.85 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GPAT as of January 2025 is 9.46. This means that GPAT is currently overvalued and has a potential downside of -6.98%.
Neither. Based on ValueRay Fundamental Analyses, GP-Act III Acquisition is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -19.85 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GPAT as of January 2025 is 9.46. This means that GPAT is currently overvalued and has a potential downside of -6.98%.
Is GPAT a buy, sell or hold?
GP-Act III Acquisition has no consensus analysts rating.
GP-Act III Acquisition has no consensus analysts rating.
What are the forecast for GPAT stock price target?
According to ValueRays Forecast Model, GPAT GP-Act III Acquisition will be worth about 10.2 in January 2026. The stock is currently trading at 10.17. This means that the stock has a potential upside of +0.49%.
According to ValueRays Forecast Model, GPAT GP-Act III Acquisition will be worth about 10.2 in January 2026. The stock is currently trading at 10.17. This means that the stock has a potential upside of +0.49%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 10.2 | 0.5% |